All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial
2021 ◽
Vol 8
(10)
◽
pp. e688-e699
◽
Keyword(s):
Phase 2
◽
2017 ◽
Vol 4
(10)
◽
pp. e487-e496
◽
2010 ◽
Vol 11
(1)
◽
pp. 29-37
◽
2017 ◽
Vol 18
(5)
◽
pp. 672-681a
◽
2019 ◽
Vol 20
(1)
◽
pp. 110-119
◽